Group 1 - The company signed an exclusive licensing agreement with Kalexo Bio, Inc. for the 2MW7141 project, which includes a total potential payment of up to $1 billion, consisting of upfront and milestone payments, as well as low single-digit royalties [2][5][11] - The agreement is expected to positively impact the company's future performance and enhance its profitability [3][11] - The 2MW7141 project is a dual-target small nucleic acid drug in the preclinical stage, aimed at regulating blood lipids and preventing high-risk cardiovascular events [6][7] Group 2 - The licensing agreement allows Kalexo exclusive rights for the global development, production, and commercialization of the licensed product [8] - The agreement includes a one-time, non-refundable upfront payment of $12 million in cash, and the company will also receive a total of double-digit A-round preferred shares from Kalexo under certain conditions [2][8] - The agreement is governed by New York law and interpreted according to California law [9] Group 3 - The company aims to leverage the collaboration with Kalexo to provide innovative treatment options for global patients, enhancing its brand value and international influence [11] - The agreement will not change the company's main business or operational scope and will not affect its independence [11]

Core Insights - Maiwei Bio has signed an exclusive licensing agreement and a preferred stock purchase agreement with Kalexo Bio, Inc. regarding the 2MW7141 project, allowing Kalexo exclusive global rights for development, production, and commercialization of the licensed product [1] - The agreements could yield up to $1 billion in upfront and milestone payments for Maiwei Bio, including an initial non-refundable payment of $12 million in cash and double-digit preferred stock in Kalexo [1] - 2MW7141 is a preclinical dual-target small nucleic acid drug aimed at lipid regulation in patients with dyslipidemia and prevention of high-risk cardiovascular events, showing strong and lasting inhibitory effects on target genes with low off-target risk [1] Company Development - The successful advancement of the 2MW7141 project validates the effectiveness of Maiwei Bio's self-developed dual/multi-target small nucleic acid drug research platform, which integrates artificial intelligence and high-throughput automated screening, significantly enhancing research efficiency [2] - The platform's modular development advantages may extend to more therapeutic areas, strengthening Maiwei Bio's strategic positioning in age-related diseases [2] Partner Company Overview - Kalexo is an innovative pharmaceutical company established by Aditum Bio Fund3, L.P., focusing on biopharmaceutical innovation through venture capital and incubation, co-founded by former Novartis executives Joe Jimenez and Mark Fishman in 2019 [2] - Aditum Bio aims to accelerate the transition of new drugs from early research to clinical stages by selecting promising, unmet medical needs in innovative drugs, therapies, or technologies with clear biological mechanisms and high clinical value [2]